Skip to content

Comparative Clinical Study of Shalmali Ghee and Shatavari Ghee in the Treatment of Abnormal Menstrual Bleeding (Asrigdar)

A Comparative Clinical Evaluation Of Shalmali Ghrit And Shatvari Ghrit In The Management Of Asrigdar - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/081379
Enrollment
60
Registered
2025-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N921- Excessive and frequent menstruation with irregular cycle

Interventions

None listed

Sponsors

Government Ayurvedic P.G. College And Hospital Chaukaghat Varanasi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are willing to participate in the trial, including both married and unmarried individuals, will be included. The primary eligibility criterion is the presence of Asrigdara as a cardinal symptom. Additionally, the study will consider patients within the age range of 18 to 45 years.

Exclusion criteria

Exclusion criteria: Patients who are not willing to participate in the trial will be excluded. Additionally, individuals with hemoglobin levels below 8 gm%, pregnant patients, and lactating women will not be considered. Those using intrauterine contraceptive devices (IUCDs) or oral contraceptive pills (OCPs) are also ineligible. Exclusion criteria further include bleeding from sites other than the uterus, bleeding due to abortion, postmenopausal bleeding, and systemic illnesses such as severe hypertension, liver dysfunction, thyroid disorders, and sexually transmitted diseases (STDs). Patients with coagulation disorders or those diagnosed with uterine and pelvic pathologies, including fibroids, adenomyosis, pelvic inflammatory disease (PID), endometrial polyps, and cervical cancer, will also be excluded from the study.

Design outcomes

Primary

MeasureTime frame
1.Normalization of Menstrual Cycle 2.Reduction in Spotting or Pre-menstrual BleedingTimepoint: 3 Months

Secondary

MeasureTime frame
Improvement in associate symptoms like angamarda kathishool aruchi daurbalya bhram tamoPravesh tandra etcTimepoint: 3 Months

Countries

India

Contacts

Public ContactDr Anjana Saxena

Government Ayurvedic PG College And Hospital Chaukaghat, Varanasi

deepikagupta0717@gmail.com9839076961

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026